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A B S T R A C T   
Oxidative distress and mitochondrial dysfunction, are key factors involved in the pathophysiology of Parkinson’s 
disease (PD). The pleiotropic hormone insulin-like growth factor II (IGF-II) has shown neuroprotective and 
antioxidant effects in some neurodegenerative diseases. In this work, we demonstrate the protective effect of IGF- 
II against the damage induced by 1-methyl-4-phenylpyridinium (MPP+) in neuronal dopaminergic cell cultures 
and a mouse model of progressive PD. In the neuronal model, IGF-II counteracts the oxidative distress produced 
by MPP + protecting dopaminergic neurons. Improved mitochondrial function, increased nuclear factor 
(erythroid-derived 2)-like2 (NRF2) nuclear translocation along with NRF2-dependent upregulation of anti-
oxidative enzymes, and modulation of mammalian target of rapamycin (mTOR) signalling pathway were iden-
tified as mechanisms leading to neuroprotection and the survival of dopaminergic cells. The neuroprotective 
effect of IGF-II against MPP + -neurotoxicity on dopaminergic neurons depends on the specific IGF-II receptor 
(IGF-IIr). In the mouse model, IGF-II prevents behavioural dysfunction and dopaminergic nigrostriatal pathway 
degeneration and mitigates neuroinflammation induced by MPP+. Our work demonstrates that hampering 
oxidative stress and normalising mitochondrial function through the interaction of IGF-II with its specific IGF-IIr 
are neuroprotective in both neuronal and mouse models. Thus, the modulation of the IGF-II/IGF-IIr signalling 
pathway may be a useful therapeutic approach for the prevention and treatment of PD.   
1. Introduction 
Parkinson’s disease (PD) is a neurodegenerative disease affecting 
2–3% of the population aged > 65 years. The pathogenesis of this dis-
ease is characterised by the involvement of multiple pathways and 
mechanisms, such as mitochondrial disfunction, oxidative stress, and 
neuroinflammation [1], that ultimately produce a loss of dopaminergic 
neurons from the substantia nigra [2,3]. Bradykinesia and other motor 
disorders are key for diagnosis, although the disease comes with other 
non-motor symptoms, such as cognitive impairment, sleep disorders, 
and depression, that increase disabilities [1]. To establish neuro-
protective strategies, it is crucial to identify new targets leading to the 
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creation of new therapeutic approaches in slowing progression and/or 
improving symptomatology [4]. 
Insulin-like growth factor II (IGF-II) is a pleiotropic hormone widely 
distributed in the Central Nervous System (CNS), where it exerts its 
functions through interactions with IGF-I receptors (IGF-Ir), insulin re-
ceptors (RIns) and its specific receptor, the IGFII/Mannose 6-Phosphate 
receptor (IGF-IIr). The genes that encode these receptors are highly 
conserved in vertebrates. In the nervous system of adults, we find a high 
expression of these receptors in the choroid plexuses, in the meninges 
and in the vascular network, as well as in the different nuclei of the 
hippocampus, cerebral cortex, cerebellum, and other areas of the 
midbrain [5] including the substantia nigra [6]. However, this growth 
factor is still poorly studied in adults. IGF-II has numerous functions 
throughout cellular homeostasis. Recently, it has been proposed that the 
effects of IGF-II, working independently or synergistically with IGF-I, 
may be relevant not only for energy homeostasis, growth, and devel-
opment, but also for learning and memory, modulating neurotransmitter 
release, adult hippocampal neurogenesis, and synaptic plasticity [7,8]. 
In addition, new evidence is emerging that IGF-II is a key neuro-
protection factor in pathological conditions. In this context, the study of 
IGF-II as a neuroprotection factor in neurodegenerative diseases is of 
increasing interest [9–11]. IGF-II has been shown to have neuro-
protective and antioxidant actions in aging conditions [12], 
glucocorticoid-mediated stress situations [13,14], neurodegenerative 
pathologies such as Alzheimer’s disease [15], and neuropsychiatric 
disorders such as schizophrenia [16,17] and autism [18]. 
The study of the mechanisms underlying this neuroprotective func-
tion of IGF-II is still in the early stages of research. A key aspect is the 
function of the specific IGF-IIr, the type of cell where it is found, and the 
nuclei that show greater expression. Associated functions include the 
clearance or activation of extracellular ligands, lysosome formation, the 
segregation and transport of lysosomal enzymes, and the activation of 
specific transduction signals, although the latter are not well known 
[9–11]. By activating these mediators (interaction with heteromeric 
G-proteins, movement of Ca2+, phosphorylation of proteins through 
PKC, and/or activation of glycogen synthase) and via mamma-
lian/mechanistic target of rapamycin (mTOR), IGF-II participates in 
fundamental nerve functions such as regulation of pro-
liferation/apoptosis, adult neurogenesis, release of neurotransmitters, 
and other synaptic factors related to memory consolidation [8,9,18–20]. 
To date, only a few studies have been published, five of which were 
by our research team, where the neuroprotection mechanisms of IGF-II 
were shown to be related to antioxidant function [10,12–14,21,22], 
supporting that IGF-II could be involved in neuroprotective actions on 
aging conditions [12], glucocorticoid-mediated stress situations [13, 
14], neurodegenerative pathologies [15], and neuropsychiatric disor-
ders [16–18]. In addition, PD is characterised by 
oxidative-mitochondrial damage, which is a major mechanism that ex-
plains the degeneration of these dopaminergic cells [2,3]. In addition, 
genetic association studies have shown the protective role of IGF-II in PD 
[23]; there is a wide distribution of IGF-IIr in different brain locations 
related with these pathologies [5,24]. 
Based on the above, we decided to study the neuroprotective effects 
of IGF-II against oxidative damage induced by 1-methyl-4-phenylpyridi-
nium (MPP+) in dopaminergic neuron cultures and 1-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP) in mice, along with the mechanisms 
involved in these effects. Although pharmacological models of PD, such 
as 6-hydroxydopamine and/or MPTP, have been questioned by its poor 
ability to identify successful disease modifying therapies, they continue 
being a valuable tool to the study of PD [25]. 
2. Material and methods 
2.1. Study design 
In this study, we assessed the antioxidant and neuroprotective effects 
of treatment with IGF-II in neuronal cell cultures and the involvement of 
its specific IGF-IIr in this effect. We also studied the effect of treatment 
with IGF-II in a mouse model of progressive PD. Animals, plates, culture 
dishes, and slides were randomised by an investigator, and the analysis 
was performed by different researchers. The minimum sample size for 
animal experiments was 10 mice per group, based on previous experi-
ence and pilot studies. In cellular experiments, a minimum of 6 exper-
iments in triplicate for each situation were performed. Further 
experimental details and technical protocols of cellular and mouse 
models are provided in the Supplementary Materials. 
2.2. Cell culture 
To develop this study, we used the SN4741 cell line of dopaminergic 
neurons of the substantia nigra [26] (provided by Prof. Ernest Arenas, 
Karolinska Institute, Stockholm). These cells express IGF-IIr as demon-
strated by the immunocytochemistry of the receptor shown in Fig. S1. 
These cells were incubated with the toxic MPP+ (400 μM) (Cas nº 
36913-39-0, SIGMA), IGF-II (25 ng/mL) (provided by Lilly Laboratories 
[Madrid, Spain]), and BMS-536924 (1 μM) (Cas nº 468740-43-4, TOC-
RIS), which inhibit the tyrosine kinase effect of the IGF-Ir and RIns. To 
reverse the effects of IGF-II mediated by its own receptor, as there are no 
specific antagonists, the antibody AF-292 (20 ng/mL) (Cat nº: AF-292- 
NA, R&D System) against the IGF-IIr was used [13,27,28]. To check 
the involvement of IGF-IIr on the main neuroprotective effects of IGF-II, 
some experiments were performed using [Leu 27]-IGF-II (LEU) (GroPep, 
Adelaide, SA, Australia) (10 nM), a specific IGF-IIr agonist that show for 
the IGF-IIr more than 100-fold higher affinity than for the IGF-I or RIns, 
and so, at the concentration used in this study we assume that only the 
IGF-IIr is stimulated. If the IGF-II effects seen in this work were mediated 
by its interaction with the specific IGF-IIr, then would be reproducible in 
presence of other agonists such as LEU [29,30]. 
The treatments were carried out in a modified Locke’s solution (NaCl 
137 mM, CaCl2 5 mM, KCl 10 mM, glucose 25 mM, Hepes 10 mM, pH: 
7.4) supplemented with penicillin-streptomycin and L-glutamine. 
The protective effects of IGF-II at the end time (6 h) (Fig. 1A) and the 
mechanisms involved with redox homeostasis, as well as the neuronal 
function at short time (2.5 h) (Figs. 2–4, A), were studied following the 
scheme shown in the figures. Experiment was performed in n = 6 each 
group (3 independent experiment). The redox parameters studied are 
presented in the scheme shown in Fig. S2. 
2.3. Viability, morphology, oxidative damage, and neurodegeneration 
Cell death was measured as the percentage of LDH released to the 
medium compared to control cells. In morphology studies, cells were 
fixed in 100% methanol and stained with Giemsa [31]. Cells were 
examined for nuclear, cytoplasmic, and cell membrane changes. 
Oxidative damage was evaluated by quantifying LOOH and AOPP using 
spectrophotometric methods [14,31]. Neurodegeneration was measured 
using Fluoro-Jade B™ dye according to a previously published proced-
ure [14]. 
2.4. Mitochondrial studies 
Mitochondrial superoxide radical production was analysed by flow 
cytometry using a dihydroetidine derivate probe [32]. Mitochondrial 
function was measured as variation in OCR by Seahorse technology, 
mΔΨ by flow cytometry using JC1 probe, and COX activity by spec-
trophotometric methods. The activity of mitochondrial SOD was quan-
tified by spectrophotometric methods. Mitochondrial morphology was 
studied by electron microscopy [31,33]. To identify and localise TFAM 
expression, a double immunocytochemical labelling experiment was 
performed using antibodies against TFAM following standard proced-
ures and the mitochondrial stain MTR and was assessed by immunocy-
tochemistry and confocal microscopy. 
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2.5. Intracellular signalling pathways 
NRF2 and phosphorylated mTOR were analysed by immunocyto-
chemistry and confocal microscopy. The activities of antioxidant en-
zymes GST and NQO1 were also quantified by spectrophotometric 
methods [31]. 
2.6. Dopamine markers 
TH and VMAT-2 were analysed by immunocytochemistry and 
confocal microscopy. DAT activity was assessed using a fluorescence- 
based assay [34]. 
2.7. MPTP/p mouse model and pharmacological treatments 
Ten-week-old male C57BL/6J mice (Janvier, Le Genest-St-Isle, 
France) were housed in groups of 3/4 in standard laboratory cages 
provided with nesting material and ad libitum access to water and food. 
Mice were maintained under a 12 h light/dark cycle (lights on at 8:00 a. 
m.) in a room with controlled temperature (22±2 ◦C), humidity, and 
ventilation. All procedures were approved by the research ethics com-
mittee of the University of Málaga (CEUMA no. 10/06/2019/104). To 
induce progressive damage in the dopaminergic nigrostriatal pathway, 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in combination with the 
clearance inhibitor probenecid (MPTP/p) was administered over 5 
weeks [35]. Probenecid was used because decreases MPTP renal elimi-
nation and helps to maintain high MPTP concentration in the brain [36]. 
Mice submitted to the MPTP/p treatment (n = 28) received intraperi-
toneal (ip) injections of probenecid (250 mg/kg, diluted initially in 1 M 
NaOH and immediately buffered in PBS at pH 7.4) followed by subcu-
taneous (sc) MPTP (24 mg/kg, diluted in 0.9% NaCl) twice a week at 84 
h intervals. Control groups (CO; n = 16) received injections of ip vehicle 
(NaOH/PBS pH 7.4) followed by sc saline on an identical administration 
regime. MPTP/p-treated and control conditions were co-administered 
with either sc IGF-II (7.5 μg/kg, diluted in phosphate-buffered saline, 
PBS 0.1 M) or vehicle twice a day at 12 h intervals, from day 1–44 
(MPTP/p + Veh, n = 8; MPTP/p+(44d) IGF-II, n = 11; CO + Veh, n = 8; 
CO + IGF-II, n = 8). Finally, a different group of mice was treated with 
IGF-II once the MPTP-induced insult has been triggered (MPTP/p+(23d) 
IGF-II, n = 9). The MPTP/p+(23d) IGF-II group received vehicle (PBS 
0.1 M) from day 1–21, after which the IGF-II co-treatment began (days 
22–44). The experimental design is depicted in Fig. 5A. 
2.8. Behavioural testing 
To investigate the recovery of the behavioural dysfunction induced 
by MPTP/p after IGF-II treatments, two different behaviours were 
assessed: motor coordination in the rotarod and self-grooming in the 
open field. Both behaviours were dependent on the integrity of the 
dopaminergic nigrostriatal pathway [37,38]. All mice were exposed to 
these two behavioural tasks under basal conditions and after the phar-
macological treatments (Fig. 5A). A detailed description of the behav-
ioural testing is available in the Supplementary Materials. 
Fig. 1. IGF-II protects SN4741 dopaminergic cells against MPP+-induced toxicity in cell cultures. (A) Experimental design for the study of the neuroprotective effects 
of IGF-II on neuronal survival and redox homeostasis. The measures were taken in SN4741 cells after 6 h of incubation with MPP+, in the presence or absence of IGF- 
II and/or BMS and AB. (B) Giemsa staining. (C) Cytotoxicity, measured by quantifying LDH release and expressed as % of control; BMS and AB are used to define the 
receptor involved in the IGF-II effect. (D) Lipid oxidative damage evaluated as LOOH; AB is used to define the receptor involved in IGF-II effect. (E) Protein oxidation 
evaluated as AOPP; AB is used to define the receptor involved in the IGF-II effect. (F) Neurodegeneration evaluated as FJ fluorescence intensity; BMS is used to define 
the receptor involved in the IGF-II effect. Data are expressed as mean ± SEM. n = 6 each group (3 independent experiment). #P < 0.05 versus CO and IGF-II groups; 
*P < 0.05, versus groups connected in bars. & P < 0.05, versus all other groups. Data were analysed by one-way ANOVA followed by Tukey’s multiple compari-
son test. 
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2.9. Immunohistochemistry for dopaminergic markers and astrogliosis 
TH, DAT, and glial fibrillary acidic protein (GFAP) diaminobenzidine 
(DAB) immunostaining was performed on striatal and SN sections. Four 
to five sections per brain containing SN or striatum were used. Total 
number of TH+ cells in SNc was counted by unbiased stereology using 
the optical fractionator method and the newCAST software (Visiopharm, 
Hoersholm, Denmark) [39]. The optical density of TH+ innervation and 
DAT immunoreactivity in the striatum and the number of striatal and 
SNc GFAP-immunoreactive astrocytes were measured from the digitised 
images using the ImageJ software (https://imagej.nih.gov/ij/). Immu-
nohistochemistry procedure and quantification details are provided in 
the Supplementary Materials. 
2.10. Measurement of the striatal MPP + levels 
C57BL/6J male mice were treated with sc IGF-II (15 μg/kg in PBS 
0.1 M) (n = 7) or vehicle (n = 8). Twenty minutes later, all mice were 
injected with ip probenecid (250 mg/kg in NaOH) followed by sc MPTP 
(30 mg/kg, diluted in 0.9% NaCl). Two hours after the MPTP dose, the 
mice were euthanised, the brains were removed, and the striatum was 
dissected, weighted, and stored at − 80 ◦C until analysis. Striatal MPP+
content was measured by liquid chromatography-mass spectrometry 
(LC-MS) as described previously [40]. Detailed procedure is provided in 
the Supplementary Materials. 
2.11. Statistical analysis 
Comparisons of multiple groups were performed using one or two- 
way Analysis of Variance (ANOVA) followed by post hoc test (Tukey’s 
post hoc test or Duncan’s multiple range test). Comparison between two 
groups was performed using Student’s unpaired t-test. Statistics were 
conducted using Statistica 8 (StatSoft Power Solutions Inc., Tulsa, OK), 
IBM SPSS 20 (IBM, Armonk, NY), and Prism 8 (GraphPad Software, San 
Diego, CA) softwares. Differences with P < 0.05 were considered sta-
tistically significant. Data are plotted as mean ± SEM. Detailed infor-
mation of the test used, including the specific post hoc test and P values, 
is stated in the figure legends. 
3. Results 
3.1. Protective role of IGF-II in a cellular model of PD 
Neurodegeneration and cellular death are triggered by many factors; 
the major factors involved and related with oxidative distress are shown 
in Fig. S2. In this work, we have studied the major factors, which are 
grouped as follows: 
3.1.1. Cellular damage: viability, morphology, oxidative damage, and 
neurodegeneration (Fig. 1A) 
To study cell viability, we resorted to the analysis of cytosolic lactate 
dehydrogenase (LDH) released after incubation with MPP+ (Fig. 1C). In 
these experiments, we found an increase of 3.5 times in LDH levels 
compared to the control; coincubation in the presence of IGF-II prevents 
Fig. 2. IGF-II protects mitochondrial function and integrity in SN4741 dopaminergic cells against MPP+-induced toxicity in cell cultures. (A) Experimental design for 
the study of the neuroprotective effects of IGF-II on mitochondrial integrity, function, and redox homeostasis. The measures were taken in SN4741 cells after 2.5 h of 
incubation with MPP+, in the presence or absence of IGF-II and/or BMS and AB. (B) OCR time course after treatments expressed as % of the control. (C) Electronic 
microscopy. (D) Mitochondrial ROS production evaluated as MitoSOX fluorescence. (E) Mitochondrial mΔΨ evaluated as JC1 fluorescence aggregates; BMS is used to 
define the receptor involved in the IGF-II effect. (F) Mitochondrial COX activity; AB is used to define the receptor involved in the IGF-II effect. (G) Mitochondrial SOD 
activity; AB is used to define the receptor involved in the IGF-II effect. (H) Representative immunocytochemistry of DAPI, TFAM, and MTR mitochondrial stain. (I) 
Quantification of TFAM immunofluorescence; AB is used to define the receptor involved in the IGF-II effect. Data are expressed as mean ± SEM. n = 6 each group (3 
independent experiment). #P < 0.05 versus CO and IGF-II groups; *P < 0.05, versus groups connected in bars; & P < 0.05, versus all other groups. Data were 
analysed by one-way ANOVA followed by Tukey’s multiple comparison test. 
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Fig. 3. IGF-II modulation of NRF2 and mTOR intracellular signalling pathways 
in SN4741 cells after MPP+-induced toxicity in cell cultures. (A) Experimental 
design for the study of the neuroprotective effects of IGF-II on NRF2 and mTOR 
intracellular signalling pathways. The measures were made in SN4741 cells 
after 2.5 h of incubation with MPP+, in the presence or absence of IGF-II and/or 
BMS and AB. (B) Representative immunocytochemistry stain for DAPI and 
NRF2 (C) Quantification of NRF2 immunofluorescence; BMS is used to define 
the receptor involved in the IGF-II effect (D) NRF2 target gene GST activity; AB 
is used to define the receptor involved in the IGF-II effect. (E) NRF2 target gene 
NQO1 activity; AB is used to define the receptor involved in the IGF-II effect. (F) 
Representative immunocytochemistry stain for DAPI and pmTOR (G) Quanti-
fication of pmTOR immunofluorescence; AB is used to define the receptor 
involved in the IGF-II effect. Data are expressed as mean ± SEM. n = 6 each 
group (3 independent experiment). #P < 0.05 versus CO and IGF-II groups; *P 
< 0.05, versus groups connected in bars; & P < 0.05, versus all other groups. 
Data were analysed by one-way ANOVA followed by Tukey’s multiple com-
parison test. 
Fig. 4. IGF-II protects SN4741 dopaminergic cells against MPP+-induced 
toxicity. (A) Experimental design for the study of the effects of IGF-II on 
dopaminergic markers. The measures were taken in SN4741 cells after 2.5 h of 
incubation with MPP+, in the presence or absence of IGF-II and/or BMS and AB. 
(B) Representative Immunocytochemistry stain for DAPI and TH. (C) Quanti-
fication of TH immunofluorescence; BMS is used to define the receptor involved 
in the IGF-II effect. (D) Representative immunocytochemistry stain for DAPI 
and VMAT2. (E) Quantification of VMAT2 immunofluorescence; AB is used to 
define the receptor involved in the IGF-II effect. (F) DAT activity; AB is used to 
define the receptor involved in the IGF-II effect. Data are expressed as mean ±
SEM. n = 6 each group (3 independent experiment). #P < 0.05, versus CO and 
IGF-II groups; *P < 0.05, versus groups connected in bars; & P < 0.05, versus all 
other groups. Data were analysed by one-way ANOVA followed by Tukey’s 
multiple comparison test. 
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Fig. 5. Chronic IGF-II administration protects against behavioural deficits and dopaminergic degeneration in the MPTP/p mouse model of progressive PD. (A) 
Experimental design. (B) Motor deficits. (C) Self-grooming deficits. (D) TH-producing dopaminergic cells in SNc. The average coefficient of error (CE) of stereological 
counting is shown for each group. (E) TH expression in the striatum (Str). (F) DAT expression in the striatum. (G) GFAP+ cells in SNc. (H) GFAP+ cells in Str. (I) 
Representative immunostaining in every experimental condition. When applicable, black arrows indicate examples of positive immunolabeling. Data are expressed as 
mean ± SEM. *P < 0.05, difference between groups; #P < 0.05, versus control groups; & P < 0.05, versus all other groups; Ø P < 0.05, versus basal. Data were 
analysed by one-way ANOVA (immunohistochemical markers) or two-way ANOVA with repeated measures (rota-rod test and self-grooming) followed by Duncan’s 
multiple range test. 
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the release of LDH induced by MPP+ (P < 0.05), with values close to that 
of the control. Incubation in the presence of BMS, an inhibitor of RIns 
and IGF-Ir, does not modify the effect of IGF-II; the addition to the in-
cubation media of the antibody against IGF-IIr abolishes the protective 
effect of IGF-II (P < 0.05). Control cells in the presence of IGF-II do not 
show any significant change compared to the control. In the study of 
morphology, the Giemsa image experiments showed clear changes in 
morphology in cells exposed to MPP+, where we found great heteroge-
neity in cell size and shape, with shrunken condensed pyknotic nuclei. 
When IGF-II was included in the treatment media, cells recovered a 
morphology similar to that of control cells. This effect on cell 
morphology was reverted in the presence of the antibody against IGF-IIr 
(Fig. 1B). 
In order to assess the oxidative damage, lipid hydroperoxide (LOOH) 
and advanced oxidation protein products (AOPP) were studied in these 
cells. LOOH and AOPP levels were increased in cells treated with MPP+
(27% and 32%, respectively) compared to the controls (P < 0.05). The 
inclusion of IGF-II in the incubation media restores LOOH and AOPP 
levels to values close to the control cells; the presence of the antibody 
against IGF-IIr in the incubation media reverted these effects (Fig. 1D 
and E). 
In the analysis of neurodegeneration assessed by Fluoro-Jade B™ 
(FJ) experiments, we found an increase in fluorescence in neurons 
treated with MPP+ (100%) compared to controls (P < 0.05). Inclusion of 
IGF-II in the incubation media restored values to those found in control 
cells. The presence of BMS in the incubation media did not modify the 
effect of IGF-II (Fig. 1F). 
3.1.2. Mitochondrial study (Fig. 2A) 
In order to evaluate mitochondrial function, oxygen consumption 
rate (OCR), free radical production, mitochondrial membrane potential 
(mΔΨ), and cytochrome c oxidase (COX) were studied in neuronal cell 
cultures. In the study of OCR, MPP+ produces a decrease (70%) after 2 h 
of incubation compared to the control (P < 0.05) (Fig. 2B). The addition 
of IGF-II in the incubation media reduces the decrease in OCR over time 
(by 50%). 
Furthermore, incubation of cells in the presence of MPP+ induces an 
increase in free radicals (Fig. 2D), leading to a significant decrease 
compared to the control, in mΔΨ (48% less than the control) and COX 
activity (68% less than control) (P < 0.05) (Fig. 2E and F). The addition 
of IGF-II in the incubation media protects mitochondria against MPP+
induced free radicals and increases mΔΨ to values close to the control 
level (Fig. 2D and E); the blockade of RIns and IGF-Ir with BMS did not 
modify the IGF-II effect. Moreover, COX activity recovered values close 
to the control when IGF-II was included in the incubation media and this 
effect was blocked by the specific IGF-IIr antibody (Fig. 2F). 
In the study of mitochondrial SOD, we found a great increase in SOD 
production (almost 150%) in cells treated with MPP+ compared to the 
control (P < 0.05); this increase was counteracted by the inclusion of 
IGF-II in the incubation media, with values close to those of control cells 
(Fig. 2G). The incorporation of antibody against IGF-IIr in the incubation 
media partially avoided the protective effect of IGF-II. 
In morphological studies at the electron microscopy level (Fig. 2C), 
we could see some differences between control and MPP+ treated cells. 
Many mitochondria were characterised by swelling, partial or total loss 
of cristae, and electron-lucent matrix. In general, we observed that 
MPP+ treatment induced a mitochondrial number reduction of 16% 
compared to control cells. When IGF-II was present in the incubation 
media, cells exhibited round or elliptical-shaped mitochondria with 
intact cristae and outer and inner membranes and no reduction in 
mitochondrial number. 
In the study of mitochondrial transcription factor A (TFAM) (Fig. 2H 
and I), we found a decrease in the cells exposed to MPP+ (38% less) 
compared to the control (P < 0.05); this was reverted in the presence of 
IGF-II to values close to the control. Incubation in the presence of 
antibody against IGF-IIr abolishes the effect of IGF-II. In the images, we 
can see a decrease in the expression of TFAM in neuronal mitochondria 
(identified by immunocytochemical staining with MitoTracker Deep 
Red FM [MTR]) compared to the control cells (P < 0.05), which was 
reverted in the presence of IGF-II. The presence of antibodies against the 
IGF-IIr abolishes the effect of IGF-II. 
3.1.3. Intracellular signalling pathways (Fig. 3A) 
NRF2 is a transcription factor that binds to antioxidant response el-
ements (ARE) in the nucleus, leading to transcription of ARE genes. In 
this work, we assessed NRF2 by immunocytochemistry (Fig. 3B and C); 
in our experiments, we could see a decrease in NRF2 expression in cells 
treated with MPP+ (26%) compared to the control (P < 0.05); supple-
mentation with IGF-II in the incubation media restores NRF2 expression 
to levels close to those of control cells (Fig. 3C). Interestingly, when 
studying nuclear NRF2 translocation, the decrease in MPP+ treated cells 
was higher (Fig. 3B); in these experiments, the inclusion of IGF-II in the 
incubation media produced an increase in nuclear fluorescence 
compared to MPP+ treated cells, recovering values close to those found 
in control cells. The presence of BMS did not modify this behaviour. 
Translocation of NRF2 to the nucleus induces the expression of some 
redox protective enzymes, such as NADPH quinone dehydrogenase 1 
(NQO1) and Glutathione S-transferase (GST). When we analysed the 
activity of NQO1 (Fig. 3E), we found a decrease of this enzyme (70%) 
compared to the control (P < 0.05). As mentioned, the inclusion of IGF-II 
in the incubation media restores NQO1 values to those of the control 
cells. In the study of GST activity (Fig. 3D), although we do not see 
variations in cells treated with MPP+, the addition of IGF-II in the in-
cubation media increases the activity compared to both MPP+ and the 
control cells (P < 0.05). It is important to note that IGF-II alone was able 
to increase the levels of GST compared to the control (P < 0.05). The 
inclusion of antibody against the IGF-IIr abolishes this effect of IGF-II. 
We have also studied, in this work, the phosphorylated form of 
mTOR protein (pmTOR). Treatment of cells with MPP+ produced a 
decrease (25%) of pmTOR compared to control cells (P < 0.05); the 
addition of IGF-II to the incubation media restores pmTOR values to 
those found in control cells (Fig. 3F and G). In addition, the inclusion of 
antibody against IGF-IIr abolishes the IGF-II effect. Interestingly, incu-
bation of cells with IGF-II in the absence of MPP+ increased the pmTOR 
values by 20% compared to the control (P < 0.05). 
3.1.4. Dopaminergic markers (Fig. 4A) 
The treatment of cells with MPP+ induced a decrease (90%) in 
tyrosine hydroxylase (TH) levels compared to the control (P < 0.05); the 
presence of IGF-II in the incubation media recovered the damage 
induced by MPP+ (70%) to values close to those of control cells. The 
inhibition of RIns and IGF-Ir by BMS in these experiments did not modify 
the TH expression (Fig. 4B and C). 
In our cellular model, treatment with MPP+ produced a decrease 
(36%) in vesicular monoamine transporter 2 (VMAT2) expression 
compared to the control (P < 0.05), as assessed by immunocytochem-
istry; the addition of IGF-II in the incubation media increased the 
expression of VMAT2 close to control levels. The inclusion of antibody 
against IGF-IIr in the media abolished the IGF-II effect, as previously 
mentioned (Fig. 4D and E). 
In the analysis of the dopamine transporter (DAT) by fluorometry, 
the treatment of cells with MPP+ totally abolished DAT activity; this is 
partially restored with the inclusion of IGF-II in the incubation media. 
The incorporation of antibody against IGF-IIr in the incubation media 
abolishes the IGF-II effect (Fig. 4F). 
3.1.5. Protective role of activation of IGF-IIr by the selective agonist LEU on 
SN4741 dopaminergic cells against MPP + -induced toxicity (HYPERLINK 
\l "appsec1" \o "appsec1"Fig. 4 supplementary) 
To assess the relevance of IGF-IIr in the main action of IGF-II we 
designed an independent study where SN4741 cells were incubated 2.5 
h or 6h with MPP+, in the presence or absence of LEU an IGF-II analogue 
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with high selective affinity for IGF-IIr. In these experiments, we found 
similar protective effects on the damage induced by MPP+, to those 
found after the stimulation with IGF-II, especially in mitochondrial ROS 
production, mΔΨ, the intracellular pathway NRF2, NQO1 enzyme and 
the dopamine marker TH after 2,5h; which results in and increase in 
survival and improves REDOX homeostasis after 6h. The incubation of 
control cell in presence of LEU did not modify ROS production (Fig. 5 
supplementary). 
3.2. Protective role of IGF-II in a mouse model of progressive PD 
Having confirmed the neuroprotective efficacy of IGF-II in dopami-
nergic SN4741 cells against the toxic MPP+, we aimed to examine 
whether IGF-II was also neuroprotective in mammals using a chronic 
progressive model of PD in mice. In this study, we employed the MPTP/p 
model (MPTP combined with probenecid), which is characterised by 
behavioural impairment, loss of striatal dopamine, degeneration of TH+
dopaminergic neurons in the pars compacta of the substantia nigra 
(SNc), and neuroinflammation [35,41]. 
In this model, we first studied relevant behaviours such as motor 
performance in the rotarod and self-grooming in an open field, as well as 
the neurodegeneration of the dopaminergic nigrostriatal pathway 
induced by MPTP/p. Regarding behavioural testing, baseline measures 
were taken immediately before the initial dose of MPTP/p (or vehicle), 
and the behavioural effects of the treatment were tested 10 days after 
the last dose of the drug (Fig. 5A). At basal conditions, before starting 
any treatment, there are no differences in latency to fall (s) in rota-rood 
nor in self-grooming among the different groups of animals, whereas 
consistent with previous reports [35,41], mice undergoing chronic 
MPTP/p treatment showed impaired performance in the rotarod (time 
spent on the rotating rod) and a dramatic reduction in the total 
self-grooming time (P < 0.05; Fig. 5B and C). 
As expected, MPTP/p-treated mice also exhibited a severe loss of 
dopaminergic neurons in the SNc (~67% less TH+ nigral neurons) and 
terminals in the striatum (>80% reduced TH and DAT expression) (P <
0.05; Fig. 5B and C), together with a significant increase in the number 
of reactive astrocytes (GFAP+ cells) in both regions (P < 0.05; Fig. 5B 
and C). 
We then investigated whether IGF-II was able to prevent the 
behavioural deficits and the nigrostriatal pathway degeneration induced 
by MPTP/p. For this purpose, a group of mice received two doses of IGF- 
II daily for 44 days, covering the whole MPTP/p administration regime 
and extending approximately a week further (Fig. 5A). We found that 
IGF-II completely prevented the development of behavioural impair-
ments (P < 0.05; Fig. 5B and C) and the loss of TH+ neurons in the SNc 
(P < 0.05; Fig. 5D), also promoting a significant recovery of the TH and 
DAT immunoreactivity in the striatum (P < 0.05; Fig. 5E and F). 
Moreover, IGF-II treatment was able to mitigate the reactive astrocytosis 
induced by MPTP/p in both SNc and the striatum (P < 0.05; Fig. 5G and 
H). 
We then studied whether IGF–II–treatment could halt the neuro-
degeneration of the dopaminergic nigrostriatal pathway and its behav-
ioural consequences once the insult has already been triggered. To do 
this, we treated a separate cohort of mice with IGF-II, starting 3 weeks 
after the first dose of MPTP/p. Remarkably, IGF-II mitigated the loss of 
dopaminergic neurons in the SNc (P < 0.05; Fig. 5D), as well as the 
reduced expression of TH and DAT in the dopaminergic terminals of the 
striatum (P < 0.05; Fig. 5E and F) and the overexpression of GFAP+
astrocytes in the SNc and striatum (P < 0.05; Fig. 5G and H). Together, 
these results suggest that IGF-II may counteract the progression of the 
nigrostriatal pathway degeneration induced by MPTP/p. However, 
behavioural studies have demonstrated that, when the progression of 
the degeneration is halted at this stage with the administration of IGF-II, 
no behavioural impairments are present in either of the two tasks (P <
0.05; Fig. 5B and C), showing that the neurodegeneration induced by 
MPTP/p is not sufficient to be reflected at the behavioural level. 
Importantly, no side effects were found after chronic injections of 
IGF-II in any of the behavioural or immunohistochemistry parameters 
studied (time on rotating rod: P > 0.05, Fig. 5B; self-grooming time: P >
0.05, Fig. 5C; TH+ neurons in SNc: P > 0.05, Fig. 5D; TH and DAT 
immunoreactivity in the striatum: P > 0.05, Fig. 5E and F; SNc and 
striatal GFAP+ astrocytes: P > 0.05, Fig. 5G and H). 
To rule out the possibility that the neuroprotection induced by IGF-II 
was related to the inhibition of the conversion of MPTP to its neurotoxic 
metabolite MPP+, we designed an independent experiment where 
striatal MPP+ levels were determined 2 h after the administration of 
MPTP/p (250 mg/kg/p; 30 mg/kg/MPTP) with or without pre- 
treatment with IGF-II (15 μg/kg). As expected, IGF-II pre-treatment 
did not alter striatal MPP+ concentrations, showing that IGF-II did not 
interfere with MPTP metabolism by the astrocytes (P > 0.05; Fig. S3). 
4. Discussion 
In PD and other neurodegenerative diseases, an increase in oxidative 
distress [42] and mitochondrial damage [3,43] that may contribute to 
increase neurodegeneration and/or cell death has been observed. The 
mechanism of cell death remains unclear, probably because instead of a 
clear apoptotic process, we faced a mixture of different processes 
recently denominated regulated cell death [44], including apoptosis, 
ferroptosis, and necrosis, as described recently in pathologies charac-
terised by cell death and inflammation, such as in some neurodegener-
ative diseases including PD [45]. Interestingly, oxidative stress may also 
be increased by other processes linked to degeneration, making it 
difficult to distinguish whether oxidative distress triggers degeneration 
or is a consequence of it [46]. 
Neuronal cells are rich in lipids, which are the target of ROS, pro-
ducing structural damage in membranes and leading to neuronal dam-
age and death. In addition, LOOH and AOPP may participate in redox 
reactions that could increase the cellular damage [47–49]. The results in 
the cellular model indicate that this protective effect is mediated by a 
decrease in oxidative damage, with concomitant decrease in LOOH and 
AOPP, protecting dopaminergic neurons from cell death, which was 
assessed as LDH release (Fig. 1D and E, C). Changes in LOOH and AOPP 
levels agree with our previous results in a cellular model of oxidative 
stress induced by corticosterone [14] and with those by Dong et al. in a 
cellular model of PD [22], where IGF-II acting on IGF-IIr restored 
oxidative balance. However, it cannot be excluded that IGF-II could 
induce an increase in the activity of the endosomal–lysosomal system 
(via the IGF-IIr) to degrade abnormal intracellular proteins induced by 
ROS [10] and/or eliminated/neutralised by detoxifying molecules such 
as GST, commented below, and other phase II enzymes [50,51]. 
Considering that oxidative distress is a common mechanism 
contributing to neurodegeneration, the effect of IGF-II reported in this 
work would be responsible of its beneficial effect and consequent 
decrease in neurodegeneration (Fig. 1F). 
PD and other neurodegenerative processes are strongly related with 
the balance in ROS production/scavenging processes [42,49], with the 
mitochondria being one of the major sources of energy and ROS pro-
duction [3,52,53]. In our PD model, as in other mitochondrial toxic 
situations, such as synucleinopathies [54], we found an increase in 
mitochondrial superoxide production that induced an increase in 
mitochondrial SOD [33,55], thereby increasing H2O2 levels, which in 
turn can inactivate some enzymes, and after interaction with Fe2+ [56], 
can induce lipid oxidation. The oxidation in the membranes of the 
mitochondria increases ROS production, which induces more lipid 
damage and neurodegeneration; furthermore, COX, the main regulatory 
enzyme of the mitochondrial respiratory chain, also gets affected, with 
impairment in neuronal energy metabolism, decrease in OCR and mΔΨ, 
and further increase in ROS production, inducing neuronal damage 
and/or death [57]. 
The protective effect of IGF-II found in our PD model and mediated 
through its specific IGF-IIr could be related to a decrease in 
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mitochondrial ROS production that prevents lipid and protein damage, 
which would result in the recovery of mitochondrial mΔΨ and OCR and 
a consequent decrease in neurodegeneration; this is consistent with our 
previous results and those of other authors [12,14,22,58,59]. The 
beneficial effect of IGF-II on mΔΨ and OCR would restore energy re-
sources contributing to maintain neuronal integrity and function, mak-
ing neurons more resistant to neurodegeneration [60]. 
Subsequently, we investigated the putative mechanisms by which 
IGF-IIr activation protects against mitochondrial oxidative damage 
induced by MPP+. This effect could be mediated by the increase in 
expression of mitochondrial transcription factors related to neurode-
generative diseases, such as TFAM, a key regulator of mtDNA abun-
dance. TFAM protects against diseases with oxidative stress and 
mitochondrial disfunction [53] and has been found to be decreased in 
PD and other neurodegenerative diseases [61]. TFAM improves Com-
plex I and IV activity in neurons and mitochondrial respiratory chain 
function, with a decrease in ROS production, increasing mtDNA and 
mitochondrial biogenesis [62,63]. In our PD model, we found an in-
crease in TFAM after treatment with IGF-II; this could be a good 
approach to either prevent or slow the progression of PD. 
One of the emerging target factors in PD and other neurodegenera-
tive diseases, related with oxidative balance, is NRF2, which induces the 
expression of an array of antioxidant response element-dependent genes 
to protect neurons from oxidative damage [64–66]. We have observed 
that the treatment of neurons with MPP+ decreases the NRF2 trans-
location to the nucleus compared to the control; this effect could be 
attributed to a decrease in NRF2 expression as suggested by Meng and 
Zhao in a model of mouse PD [67,68], or to an alteration in NRF2 
metabolism as suggested by Li [69] and/or to a decrease in translocation 
by itself induced by the toxic as suggested by Li and Kasai [70,71]; in any 
case, IGF-II through the IGF-IIr, recovers that decrease. 
Furthermore, NRF2 induces the expression of antioxidant enzymes 
[64], which is in agreement with our results discussed below; moreover, 
activation of the NRF2 pathway improves mitochondrial bioenergetics, 
function [72], and cell metabolism, as discussed above. NRF2 may also 
be responsible for the increase in TFAM levels described in this model, 
consistent with previous works [73,74]. We also examined two final 
products of these antioxidant response dependent genes, GST and 
NQO1. 
GST is a detoxifying phase II enzyme that plays an essential role as an 
antioxidant in maintaining the redox balance in neurons, catalysing the 
reduction of ROS by glutathione and rendering these molecules more 
soluble to be eliminated by the neurons [64,75]. On the contrary, in PD, 
over-expression of GST isoenzyme 1 in dopaminergic neurons decreased 
neurodegeneration, suggesting a protective effect of this enzyme [76, 
77]. Although no great variations in GST activity were seen after 
treatment with MPP+ by other authors [77], we observed an increase in 
GST in control neurons after treatment with IGF-II. This increase was 
even higher when neurons were previously exposed to MPP+; however, 
we do not have a clear explanation for this finding. The IGF-II effect was 
mediated by the interaction with its specific IGF-IIr. 
NQO1 is also a detoxifying phase II enzyme that catalyses the 
reduction of quinone species and that can be produced during the 
metabolism of dopamine to the less toxic hydroquinone, suggesting that 
it may be a protective mechanism for oxidative damage in PD [26,78, 
79]. We found a decrease in NQO1 activity after treatment with MPP+, 
which is consistent with the findings of other authors [79–81]. This ef-
fect was avoided in the presence of IGF-II, thereby recovering activities 
close to those found in control neurons; as mentioned previously, this 
effect was mediated by interaction with its specific IGF-IIr. 
mTOR is an important regulator of neuron metabolism, mitochon-
drial homeostasis, protein synthesis, and cell death [82]. Alteration in 
the mTOR pathway has been found in some neurodegenerative diseases 
such as PD, Alzheimer’s disease, Huntington’s disease, or amyotrophic 
lateral sclerosis [83–86]. In this work, incubation of neurons with MPP+
decreased phospho-mTOR1 (pmTOR) levels, which is similar to the 
findings of other studies [83,87]; addition of IGF-II to the incubation 
media prevented the fall in pmTOR levels. This was mediated through its 
specific IGF-IIr. This increase in pmTOR could be due to an increase in 
NRF2 levels as demonstrated by others [88,89] as well as our findings. 
Moreover, it has been described the stimulation of pmTOR by neuro-
transmitters, such as dopamine [86,90], and as commented below, we 
have found an increase in TH, the limiting enzyme in dopamine syn-
thesis, that could promote the increase in pmTOR. Interestingly, when 
we assessed the effect of IGF-II on control cells, we found an increase in 
pmTOR that could be related with the known metabolic and neuro-
trophic factor effect of IGF-II [12,91]. 
Decrease in dopamine synthesis is one of the hallmarks in PD [45], 
with TH being the limiting enzyme in dopamine synthesis; an increase in 
TH immunoreactivity after treatment with IGF-II has been reported 
[92]. The treatment of cells with MPP+ (Fig. 4B and C) induces a 
decrease in the level of this enzyme compared to the control; the pres-
ence of IGF-II in the incubation media not only restores but also in-
creases TH expression above that of the control cells. Interestingly, a 
similar increase was seen in the control cells in the presence of IGF-II, 
which is in agreement with the results of the study by Pai et al., who 
found that increased IGF-II may induce an increase in TH and dopamine 
synthesis [93]. This effect must be mediated by IGF-II interaction with 
its specific IGF-IIr. 
Once synthesised, dopamine is stored in vesicles by VMAT2 to avoid 
its autooxidation and deleterious effect. Treatment with MPP+ produces 
a decrease in VMAT2 expression and the inclusion of IGF-II in the in-
cubation media recovers the expression of VMAT2 close to control 
levels, probably due to the increase in its synthesis at the trans-Golgy 
network, this effect is attributable to the interaction of IGF-II with its 
specific IGF-IIr. The increase in VMAT2 would decrease the level of 
cytosolic dopamine, avoiding its oxidation and ROS production [75]. 
Cytosolic dopamine levels are not only regulated by VMAT2 but also 
highly influenced by DAT, and a correct balance between VMAT2 and 
DAT is essential in PD for both neurotransmission and cell survival [94]. 
The treatment of cells with MPP+ totally abolished DAT activity 
(Fig. 4F), which was partially restored with the inclusion of IGF-II in the 
incubation media; this effect is mediated by the interaction with IGF-IIr. 
The mechanism of IGF-II effect on DAT could be related with the 
decrease in PKC activity induced by IGF-II, as previously described [14], 
which induces a downregulation of DAT [95]. IGF-II did not interfere 
with MPP+ neuronal uptake through DAT, excluding the neuro-
protective role of IGF-II, which could be explained by this mechanism. 
The neuroprotective properties of the IGF-II in dopaminergic neu-
rons were also demonstrated in a mouse model of progressive PD 
induced by the chronic administration of MPTP/p. This model of PD 
involves the degeneration of the nigrostriatal dopaminergic neurons by 
the conversion of the MPTP into the neurotoxic metabolite MPP+ in the 
astrocytes, which is uptake by dopaminergic neurons and rise ROS 
production and induce mitochondrial dysfunction [42]; also MPTP in-
creases synuclein (A-syn) expression in dopaminergic neurons which in 
turn can further enhance ROS production and impair mitochondria, 
leading to dopaminergic neurodegeneration and neuronal death [44,96, 
97]. 
Even when we have not studied the mechanisms of action of IGF-II in 
vivo, our cellular results strongly support the capacity of the IGF-II to 
prevent the oxidative damage and mitochondrial dysfunction induced 
by MPP+. In this regard, we demonstrated that IGF-II did not interfere 
either with the glial formation of MPP+ (Fig. S3) or with its neuronal 
uptake through DAT (Fig. 4F), ruling out that the neuroprotective role of 
the IGF-II in the nigrostriatal pathway could be explained through these 
mechanisms. In addition to the ability of the IGF-II to counteract the 
oxidative damage in the dopaminergic neurons, it may exert 
neuroprotective/anti-parkinsonian actions in vivo, involving other 
complementary mechanisms such as neuroinflammation, autophagy, 
and protein trafficking of damaged molecules [10,59,98] that cannot be 
ruled out in our study. Regarding this, our data showed an evident 
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neuroinflammation in both the striatum and SNc in MPTP/p-treated 
mice (reactive astrocytes overexpression; Fig. 5G and H), and IGF-II 
administration was able to reduce this inflammatory response. Thus, it 
has also been demonstrated that IGF-II can attenuate and even normalise 
neuroinflammation in pathological conditions [10,99], thereby 
contributing to the neuroprotective effects observed in IGF–II–treated 
mice. Although the study of A-syn in the animal model was out of the 
scope of this work, we cannot rule out the involvement of A-syn in the 
neuroprotective effect of IGF-II on this model, as it has been reported 
that impairment of IGF-I and IGF-II signalling tend to increase A-syn 
accumulation and increase oxidative stress [100]. 
Due to the lack of selective pharmacological tools, the study in the 
animal model was limited in that we were unable to examine the 
involvement of the IGF-IIr in the neuroprotection of the dopaminergic 
pathway mediated by IGF-II; even though, based on the results obtained 
in the cellular experiments, including those with the IGF-IIr specific 
agonist LEU shown in supplementary, we would expect that most, if not 
all, of these effects would be linked to the activation of the IGF-IIr. 
In summary, in both models of MPP+/MPTP induced PD used in this 
study, we have reported an increase in neurodegeneration and cell 
death, with impaired neuronal function as a consequence of increase in 
oxidative distress and mitochondrial dysfunction. Interaction of IGF-II 
with its specific IGF-IIr showed neuroprotective actions by promoting 
NRF-2 and mTOR antioxidant pathways and restoring mitochondrial 
and neuronal function. The involvement of IGF-IIr in these effects was 
demonstrated using LEU, as this specific IGF-IIr agonist was able to 
preproduce the IGF-II actions. 
5. Conclusions 
In conclusion, we demonstrated the potential neuroprotective role of 
IGF-II in a cellular and a mouse model of PD. In both models, we 
confirmed the ability of IGF-II to protect dopaminergic neurons against 
the oxidative damage induced by the neurotoxin MPP+. Considering the 
beneficial effects of IGF-II reported both in cellular and animal models; 
and the role of the IGF-IIr demonstrated in the cellular experiments, we 
propose that the modulation of the IGF-II/IGF-IIr signalling pathway be 
considered a promising pharmacological target for the treatment of PD. 
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[28] E. Martin-Montañez, J. Pavia, L.J. Santin, F. Boraldi, G. Estivill-Torrus, J. 
A. Aguirre, M. Garcia-Fernandez, E. Martin-Montanez, J. Pavia, L.J. Santin, 
F. Boraldi, G. Estivill-Torrus, J.A. Aguirre, M. Garcia-Fernandez, Involvement of 
IGF-II receptors in the antioxidant and neuroprotective effects of IGF-II on adult 
cortical neuronal cultures, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1842 
(2014) 1041–1051, https://doi.org/10.1016/j.bbadis.2014.03.010. 
[29] M.W. Beukers, Y. Oh, H. Zhang, N. Ling, R.G. Rosenfeld, [Leu 27 ] INSULIN-LIKE 
growth factor II IS highly selective for the TYPE-II igf receptor IN binding, CROSS- 
LINKING and thymidine incorporation experiments, Endocrinology 128 (1991) 
1201–1203, https://doi.org/10.1210/endo-128-2-1201. 
[30] A. Amritraj, E.I. Posse de Chaves, C. Hawkes, R.G. MacDonald, S. Kar, Single- 
transmembrane domain IGF-II/M6P receptor: potential interaction with G protein 
and its association with cholesterol-rich membrane domains, Endocrinology 153 
(2012) 4784–4798, https://doi.org/10.1210/en.2012-1139. 
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E. Martín-Montañez et al.                                                                                                                                                                                                                     
Redox Biology 46 (2021) 102095
12
[59] X. Wang, L. Lin, B. Lan, Y. Wang, L. Du, X. Chen, Q. Li, K. Liu, M. Hu, Y. Xue, A. 
I. Roberts, C. Shao, G. Melino, Y. Shi, Y. Wang, IGF2R-initiated proton 
rechanneling dictates an anti-inflammatory property in macrophages, Sci. Adv. 6 
(2020), https://doi.org/10.1126/sciadv.abb7389 eabb7389. 
[60] V.R. Muddapu, S.A.P. Dharshini, V.S. Chakravarthy, M.M. Gromiha, 
Neurodegenerative diseases – is metabolic deficiency the root cause? Front. 
Neurosci. 14 (2020) 213, https://doi.org/10.3389/fnins.2020.00213. 
[61] I. Kang, C.T. Chu, B.A. Kaufman, The mitochondrial transcription factor TFAM in 
neurodegeneration: emerging evidence and mechanisms, FEBS Lett. 592 (2018) 
793–811, https://doi.org/10.1002/1873-3468.12989. 
[62] N. Morimoto, K. Miyazaki, T. Kurata, Y. Ikeda, T. Matsuura, D. Kang, T. Ide, 
K. Abe, Effect of mitochondrial transcription factor a overexpression on motor 
neurons in amyotrophic lateral sclerosis model mice, J. Neurosci. Res. 90 (2012) 
1200–1208, https://doi.org/10.1002/jnr.23000. 
[63] Y. Piao, H.G. Kim, M.S. Oh, Y.K. Pak, Overexpression of TFAM, NRF-1 and myr- 
AKT protects the MPP+-induced mitochondrial dysfunctions in neuronal cells, 
Biochim. Biophys. Acta Gen. Subj. 1820 (2012) 577–585, https://doi.org/ 
10.1016/j.bbagen.2011.08.007. 
[64] Q. Ma, Role of Nrf2 in oxidative stress and toxicity, Annu. Rev. Pharmacol. 
Toxicol. 53 (2013) 401–426, https://doi.org/10.1146/annurev-pharmtox- 
011112-140320. 
[65] N. Esteras, A.T. Dinkova-Kostova, A.Y. Abramov, Nrf2 activation in the treatment 
of neurodegenerative diseases: a focus on its role in mitochondrial bioenergetics 
and function, Biol. Chem. 397 (2016) 383–400, https://doi.org/10.1515/hsz- 
2015-0295. 
[66] M.S. Brandes, N.E. Gray, NRF2 as a therapeutic target in neurodegenerative 
diseases, ASN Neuro 12 (2020), https://doi.org/10.1177/1759091419899782, 
175909141989978. 
[67] M. Zhao, B. Wang, C. Zhang, Z. Su, B. Guo, Y. Zhao, R. Zheng, The DJ1-Nrf2- 
STING axis mediates the neuroprotective effects of Withaferin A in Parkinson’s 
disease, Cell Death Differ. 28 (2021) 2517–2535, https://doi.org/10.1038/ 
s41418-021-00767-2. 
[68] F. Meng, J. Wang, F. Ding, Y. Xie, Y. Zhang, J. Zhu, Neuroprotective effect of 
matrine on MPTP-induced Parkinson’s disease and on Nrf2 expression, Oncol. 
Lett. 13 (2017) 296–300, https://doi.org/10.3892/OL.2016.5383. 
[69] L. Q, N. C, Z. X, D. M, Gastrodin and isorhynchophylline synergistically inhibit 
MPP +-Induced oxidative stress in SH-SY5Y cells by targeting ERK1/2 and GSK- 
3β pathways: involvement of Nrf2 nuclear translocation, ACS Chem. Neurosci. 9 
(2018) 482–493, https://doi.org/10.1021/ACSCHEMNEURO.7B00247. 
[70] X. Li, J. Zhang, X. Zhang, M. Dong, Puerarin suppresses MPP+/MPTP-induced 
oxidative stress through an Nrf2-dependent mechanism, Food Chem. Toxicol. 144 
(2020) 111644, https://doi.org/10.1016/J.FCT.2020.111644. 
[71] S. Kasai, S. Shimizu, Y. Tatara, J. Mimura, K. Itoh, Regulation of nrf2 by 
mitochondrial reactive oxygen species in physiology and pathology, Biomolecules 
10 (2020), https://doi.org/10.3390/BIOM10020320. 
[72] A.T. Dinkova-Kostova, A.Y. Abramov, The emerging role of Nrf2 in mitochondrial 
function, Free Radic. Biol. Med. 88 (2015) 179–188, https://doi.org/10.1016/j. 
freeradbiomed.2015.04.036. 
[73] K.U. Tufekci, E. Civi Bayin, S. Genc, K. Genc, The nrf2/ARE pathway: a promising 
target to counteract mitochondrial dysfunction in Parkinson’s disease, 
Parkinsons. Dis. (2011) 1–14, https://doi.org/10.4061/2011/314082, 2011. 
[74] M.-H. Fu, C.-W. Wu, Y.-C. Lee, C.-Y. Hung, I.-C. Chen, K.L.H. Wu, Nrf2 activation 
attenuates the early suppression of mitochondrial respiration due to the 
α-synuclein overexpression, Biomed. J. 41 (2018) 169–183, https://doi.org/ 
10.1016/j.bj.2018.02.005. 
[75] M. Smeyne, R.J. Smeyne, Glutathione metabolism and Parkinson’s disease, Free 
Radic. Biol. Med. 62 (2013) 13–25, https://doi.org/10.1016/j. 
freeradbiomed.2013.05.001. 
[76] F. Pohl, A. Teixeira-Castro, M.D. Costa, V. Lindsay, J. Fiúza-Fernandes, M. Goua, 
G. Bermano, W. Russell, P. Maciel, P. Kong Thoo Lin, GST-4-Dependent 
suppression of neurodegeneration in C. elegans models of Parkinson’s and 
machado-joseph disease by rapeseed pomace extract supplementation, Front. 
Neurosci. 13 (2019) 1091, https://doi.org/10.3389/fnins.2019.01091. 
[77] M. Smeyne, J. Boyd, K.R. Shepherd, Y. Jiao, B.B. Pond, M. Hatler, R. Wolf, 
C. Henderson, R.J. Smeyne, GSTπ expression mediates dopaminergic neuron 
sensitivity in experimental parkinsonism, Proc. Natl. Acad. Sci. U.S.A. 104 
(2007), https://doi.org/10.1073/pnas.0610978104, 1977–1982. 
[78] S. Luo, S.S. Kang, Z.-H. Wang, X. Liu, J.X. Day, Z. Wu, J. Peng, D. Xiang, 
W. Springer, K. Ye, Akt phosphorylates NQO1 and triggers its degradation, 
abolishing its antioxidative activities in Parkinson’s disease, J. Neurosci. 39 
(2019) 7291–7305, https://doi.org/10.1523/JNEUROSCI.0625-19.2019. 
[79] H. Xiao, F. Lv, W. Xu, L. Zhang, P. Jing, X. Cao, Deprenyl prevents MPP+-induced 
oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 
expression through the activation of PI3K/Akt and Erk, Toxicology 290 (2011) 
286–294, https://doi.org/10.1016/j.tox.2011.10.007. 
[80] G. Armagan, E. Sevgili, F.T. Gürkan, F.A. Köse, T. Bilgiç, T. Dagcı, L. Saso, 
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